Vapreotide
Also known as: RC-160, RC‑160, Sanval, vapreotide acetate
Source Vapreotide at Peptiology
Save 10% with code PEPTI-BOSSRABBIT-10
Tapping Shop Now & Save 10% copies your 10% off code PEPTI-BOSSRABBIT-10 to your clipboard. Paste it at the Peptiology checkout to claim the discount.
Summary
Vapreotide (RC‑160) is a synthetic octapeptide somatostatin analogue used intravenously or subcutaneously to control acute variceal hemorrhage and to suppress pancreatic secretions.
Mechanism of Action
High‑affinity agonist of somatostatin receptors (SSTR2, SSTR5) leading to inhibition of hormone secretion, reduction of splanchnic blood flow and portal pressure.
Routes of Administration
Goals & Uses
- Carcinoid syndrome and neuroendocrine tumorsOncologyLow
- Acromegaly managementEndocrinologyLow
- Pancreatic fistula preventionSurgeryLow
- Control of acute variceal bleedingHemostasis / GastroenterologyHigh
- Inhibition of pancreatic exocrine secretionGastrointestinalModerate
- Acute esophageal variceal bleedingGastroenterologyModerate
Contraindications
- Hypersensitivity to vapreotide or somatostatin analoguesAllergyHigh
- Hypersensitivity to vapreotide or any excipientAllergyHigh
- PregnancyPopulationModeratePotential fetal risk or insufficient safety data
Adverse Effects
- HyperglycemiaMetabolicUncommonAbnormally high blood glucose
- Hyperglycemia or hypoglycemiaMetabolic/EndocrineUncommon
- Injection site reactionsLocalCommon
- Gallstone formationHepatobiliaryUncommon
- Nausea and vomitingGastrointestinalCommon
- NauseaGastrointestinalCommonFeeling of sickness or urge to vomit
- Injection site reactionLocalCommonRedness, swelling, itching, bruising, or pain at the injection site
- BradycardiaCardiovascularUncommon
- Abdominal painGastrointestinalCommonPain or discomfort in the abdomen
Drug Interactions
- Insulin and oral hypoglycemicsModerate
- Beta-blockersModerate
- Other somatostatin analoguesLow
- CyclosporineModerate
Population Constraints
- Renal impairmentOrgan ImpairmentRelative
- Pediatric patientsAgeRelative
- Pediatric populationAgeRelative
- Patients with cholelithiasisHepatobiliaryRelative
- Elderly (>75 y)AgeRelative
- Diabetic PatientsMetabolicRelative
Regulatory Status
- European UnionUnapprovedNo marketing authorization in European Union.
- United StatesUnapprovedNot submitted for FDA approval.
- United KingdomUnapprovedNot licensed by MHRA.
Vapreotide has not received FDA or EMA approval for any indication. It has been investigated in clinical trials for esophageal variceal bleeding and acromegaly. Developed by Debio/Biomeasure; limited commercial development followed.
Evidence & Sources
No sources recorded yet.
Frequently Asked Questions
What is Vapreotide?
Vapreotide (RC‑160) is a synthetic octapeptide somatostatin analogue used intravenously or subcutaneously to control acute variceal hemorrhage and to suppress pancreatic secretions.
What is Vapreotide used for?
Vapreotide is educationally associated with: Carcinoid syndrome and neuroendocrine tumors, Acromegaly management, Pancreatic fistula prevention, Control of acute variceal bleeding, Inhibition of pancreatic exocrine secretion, Acute esophageal variceal bleeding. Educational only — not medical advice.
How is Vapreotide administered?
Recorded routes of administration: Intravenous, Subcutaneous.
What are the potential side effects of Vapreotide?
Reported adverse effects include: Hyperglycemia, Hyperglycemia or hypoglycemia, Injection site reactions, Gallstone formation, Nausea and vomiting, Nausea, Injection site reaction, Bradycardia, Abdominal pain. This list is not exhaustive — consult a qualified clinician.
Who should avoid Vapreotide?
Recorded contraindications: Hypersensitivity to vapreotide or somatostatin analogues, Hypersensitivity to vapreotide or any excipient, Pregnancy. Consult a qualified clinician before use.